Voronoi, Inc.
Financials
Valuation Metrics
Voronoi, Inc.'s Market Cap is ₩2.1T. At end of 2025 it was ₩4.0T. Ranked #188 of 2,414 in KR market (top 8%), #31 of 1,633 on KOSDAQ (top 2%), #13 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 6%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 2.14T KRW | KR#188/2,414 Sec#13/231 |
| Revenue | 4.16B KRW | KR#2,346/2,414 Sec#202/231 |
| Net Income | -69.13B KRW | KR—/2,414 Sec—/231 |
| Total Assets | 133.72B KRW | KR#1,583/2,414 Sec#123/231 |
| Net Assets | 69.18B KRW | KR#1,690/2,414 Sec#142/231 |
| Employees | 147 | KR#1,340/2,414 Sec#108/231 |
| Value | ||
| P/B | 30.89x | KR#2,404/2,414 Sec#229/231 |
| P/S | 513.49x | KR#2,402/2,414 Sec#224/231 |
| FCF Yield | -3.45% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | -99.94% | KR#2,339/2,414 Sec#218/231 |
| ROA | -51.70% | KR#2,361/2,414 Sec#216/231 |
| Op. Margin | -1947.05% | KR#2,379/2,414 Sec#220/231 |
| Revenue Growth | 24.23% | KR#470/2,414 Sec#45/231 |
| Financial Health | ||
| Debt Ratio | 93.30% | KR#1,488/2,414 Sec#172/231 |
| Total Debt | 31.05B KRW | KR#1,211/2,414 Sec#90/231 |
| FCF | -73.74B KRW | KR#2,107/2,414 Sec#208/231 |
| Cash | 24.83B KRW | KR#1,115/2,414 Sec#75/231 |
| Current Ratio | 9.46x | KR#110/2,414 Sec#26/231 |
| Performance | ||
| 1Y Return | -29.00% | KR#1,441/2,414 Sec#110/231 |
| 1M Return | -18.75% | KR#2,132/2,414 Sec#202/231 |
| From 52W High | -69.43% | KR#2,082/2,414 Sec#175/231 |
| 1Y MDD | -72.27% | KR#2,074/2,414 Sec#182/231 |
| Trading | ||
| Volume | 60,592 shares | KR#1,251/2,414 Sec#125/231 |
| Trading Value | 6.89B KRW | KR#314/2,414 Sec#23/231 |
| Foreign Own. | 6.26% | KR#704/2,414 Sec#62/231 |
| Per Share | ||
| EPS | -3,714 KRW | KR—/2,414 Sec—/231 |
| BPS | 3,716 KRW | KR#1,732/2,414 Sec#126/231 |
Company Info
Established in 2015 in Songdo, Incheon, VORONOI is a new drug development venture company with its own medicinal chemistry research institute. It specializes in developing targeted anticancer drugs for conditions like lung and breast cancer, with VRN11 currently undergoing global clinical phase 1 trials after approvals in Korea, Taiwan, and Hong Kong. The company utilizes its Voronomix platform to accelerate drug development from target selection to candidate substance in 1-1.5 years, demonstrating competitiveness through five technology transfer achievements since 2020. VORONOI is headquartered in Yeonsu-gu, Incheon Metropolitan City.